Protein adducts as prospective biomarkers of nevirapine toxicity.
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used against human immunodeficiency virus type-1 (HIV-1), mostly to prevent mother-to-child HIV-1 transmission in developing countries. Despite its clinical efficacy, NVP administration is associated with a variety of toxic responses that include hepatotoxicity and skin rash. Although the reasons for the adverse effects of NVP administration are still unclear, increasing evidence supports the involvement of metabolic activation to reactive electrophiles. In particular, Phase II activation of the NVP metabolite 12-hydroxy-NVP is thought to mediate NVP binding to bionucleophiles, which may be at the onset of toxicity. In the present study, we investigated the nature and specific locations of the covalent adducts produced in human serum albumin and human hemoglobin by reaction in vitro with the synthetic model electrophile 12-mesyloxy-NVP, used as a surrogate for the Phase II metabolite 12-sulfoxy-NVP. Multiple sites of modification were identified by two different mass spectrometry-based methodologies, liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) and matrix-assisted laser desorption ionization tandem mass spectrometry (MALDI-TOF-TOF-MS). These two distinct methodologies, which in some instances afforded complementary information, allowed the identification of multiple adducts involving cysteine, lysine, tryptophan, histidine, serine, and the N-terminal valine of hemoglobin. Tryptophan, which is not a common site of covalent protein modification, was the NVP-modified amino acid residue detected in the two proteins and consistently identified by both LC-ESI-MS/MS and MALDI-TOF-TOF-MS. The propensity of tryptophan to react with the NVP-derived electrophile is further emphasized by the fact that human serum albumin possesses a single tryptophan residue, which suggests a remarkable selectivity that may be useful for biomonitoring purposes. Likewise, the NVP adduct with the terminal valine of hemoglobin, detected by LC-ESI-MS/MS after N-alkyl Edman degradation, appears as an easily assessed marker of NVP binding to proteins. Our results demonstrate the merits and complementarity of the two MS-based methodologies for the characterization of protein binding by NVP and suggest a series of plausible biomarkers of NVP toxicity that should be useful in the monitoring of toxicity effects in patients administered NVP.
Antunes
Alexandra M M
AM
Centro de Química Estrutural, Instituto Superior Técnico, Universidade Técnica de Lisboa, Lisboa, Portugal. alexandra.antunes@ist.utl.pt
Godinho
Ana L A
AL
Martins
Inês L
IL
Oliveira
M Conceição
MC
Gomes
Ricardo A
RA
Coelho
Ana V
AV
Beland
Frederick A
FA
Marques
M Matilde
MM
D000595:Amino Acid Sequence; D019380:Anti-HIV Agents / Q000378:metabolism* / Q000627:therapeutic use / Q000633:toxicity; D015415:Biomarkers / Q000737:chemistry*; D002851:Chromatography, High Pressure Liquid; D015658:HIV Infections / Q000188:drug therapy; D006454:Hemoglobins / Q000737:chemistry; D006801:Humans; D008698:Mesylates / Q000633:toxicity; D008969:Molecular Sequence Data; D019829:Nevirapine / Q000031:analogs & derivatives / Q000378:metabolism* / Q000627:therapeutic use / Q000633:toxicity; D018894:Reverse Transcriptase Inhibitors / Q000378:metabolism* / Q000627:therapeutic use / Q000633:toxicity; D012709:Serum Albumin / Q000737:chemistry; D021241:Spectrometry, Mass, Electrospray Ionization; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D014364:Tryptophan / Q000737:chemistry
C551532:12-mesyloxynevirapine; D019380:Anti-HIV Agents; D015415:Biomarkers; D006454:Hemoglobins; D008698:Mesylates; D018894:Reverse Transcriptase Inhibitors; D012709:Serum Albumin; D014364:Tryptophan; D019829:Nevirapine
Chem Res Toxicol. 2010 May 17;23(5):888-99
20392079
Drug Metab Dispos. 1999 Aug;27(8):895-901
10421616
Chem Res Toxicol. 2003 Sep;16(9):1078-89
12971795
FEBS J. 2005 Jan;272(2):353-62
15654874
Methods Enzymol. 1994;231:650-7
8041284
Chem Res Toxicol. 2008 Jul;21(7):1443-56
18597499
Chem Res Toxicol. 2008 Jan;21(1):117-28
18052106
J Chromatogr A. 2007 Oct 12;1167(2):125-34
17826786
Drug Metab Dispos. 2010 Jan;38(1):122-32
19797610
N Engl J Med. 2004 Jul 15;351(3):217-28
15247338
Toxicol Sci. 2009 Apr;108(2):401-11
19221146
Int J Clin Pract. 2007 Jan;61(1):105-18
17229185
Curr Opin Allergy Clin Immunol. 2009 Aug;9(4):311-5
19535973
Contact Dermatitis. 2005 Oct;53(4):189-200
16191014
JAMA. 2008 Aug 6;300(5):555-70
18677028
Annu Rev Pharmacol Toxicol. 2007;47:513-39
16879083
Int J Hyg Environ Health. 2007 May;210(3-4):201-28
17376741
Drug Metab Dispos. 2008 Sep;36(9):1770-9
18508880
J Clin Oncol. 2009 Feb 20;27(6):884-90
19114688
Chem Res Toxicol. 2006 Jul;19(7):889-93
16841955
Chem Res Toxicol. 2008 Sep;21(9):1862-70
18729332
Clin Ther. 1998 Nov-Dec;20(6):1071-92
9916603
Chem Res Toxicol. 2005 Dec;18(12):1799-813
16359170
Annu Rev Pharmacol Toxicol. 2005;45:177-202
15822174
J Biol Chem. 1986 May 25;261(15):6747-57
3009475
Electrophoresis. 1988 Jun;9(6):255-62
2466658
Drug Metab Rev. 2005;37(1):41-213
15747500
Chem Res Toxicol. 2006 Sep;19(9):1205-14
16978025
Drug Metab Dispos. 2009 Jul;37(7):1557-62
19364830
Lancet. 2003 Sep 13;362(9387):859-68
13678973
HIV Med. 2008 Feb;9(2):72-81
18257770
Drug Metab Dispos. 1999 Dec;27(12):1488-95
10570031
N Engl J Med. 1972 Apr 6;286(14):748-57
4554517
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Oct 5;778(1-2):279-308
12376136
Drug Metab Dispos. 1999 Dec;27(12):1434-47
10570025
Clin Pharmacokinet. 2000 Oct;39(4):281-93
11069214
Lancet. 1999 Sep 4;354(9181):803-9
10485721
Anal Biochem. 1999 Apr 10;269(1):143-8
10094785
Environ Health Perspect. 1993 Mar;99:51-5
8319659
Biochem J. 2008 Dec 15;416(3):317-26
18651835
J Chromatogr A. 2007 Jul 20;1157(1-2):10-6
17467723
N Engl J Med. 2007 Jan 11;356(2):135-47
17215531
Mass Spectrom Rev. 2009 Sep-Oct;28(5):725-84
19127566
Rapid Commun Mass Spectrom. 2007;21(16):2734-42
17654464
Biochem Pharmacol. 1993 Jan 26;45(2):271-9
8435087
Biomed Chromatogr. 2010 Jul;24(7):717-26
19882749